US FDA May Reconsider RMAT Requests If Resubmitted With Sufficient Clinical Data
Executive Summary
Rejection of an RMAT request does not mean necessarily mean the FDA won't grant one. The agency will accept new clinical data to support the application through a “reconsideration” process, industry official says.